Company / Net Income
Cullinan Therapeutics, Inc. Net Income History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$167.4M
FY2024
5-year range
-$167.4M / $111.2M
FY2020-FY2024
Trend
-9.3%
vs FY2023
Sector context
#141 of 216
Health Care
What the data says
At -$167M, Cullinan Therapeutics, Inc.'s net income ranks #141 of 216 in the Health Care sector. Declined from $111M to -$167M over the past 2 years.
Based on SEC 10-K filings.
-$167M in FY2024.
Declined from $111M to -$167M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#141 of 216 in Health CareTop 65% of 216This company -$167.4M Sector average $454.1M
▼
-136.9% below sector average
Key checks
Key Insights
- In FY2024, net income decreased 9.3% year-over-year.
- Ranks #141 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 7.33 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$167.4M | -9.3% |
| FY2023 | -$153.2M | -237.7% |
| FY2022 | $111.2M | +314.7% |
| FY2021 | -$51.8M | +0.0% |
| FY2020 | -$51.8M | - |
As of FY2024 · SEC 10-K · Updated Jul 2, 2026